Personalis NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study
I'm PortAI, I can summarize articles.
Personalis, Inc. announced results from a clinical study using its NeXT Personal® test for detecting molecular residual disease in non-small cell lung cancer. The study, published in Cell, analyzed 431 patients over five years, showing high sensitivity in detecting circulating tumor DNA. Key findings include detection of residual and recurrent cancer at multiple stages, with 36-43% in the ultrasensitive range. Patients not clearing ctDNA during chemotherapy were more likely to relapse. Results were published in Cell.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments